Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Danaher to Acquire Cepheid for USD 4 Billion

By LabMedica International staff writers
Posted on 07 Sep 2016
Danaher Corporation (Washington, D.C., USA) will acquire Cepheid (Sunnyvale, California, USA) by purchasing all of the company’s outstanding shares for $53.00 per share in cash, or a total enterprise value of approximately USD 4 billion, including indebtedness and net of acquired cash.

Cepheid develops, manufactures, and markets molecular systems and tests, and has the largest global installed base of instruments as well as the broadest test menu in molecular diagnostics. More...
The company will now become part of Danaher's USD 5 billion Diagnostics segment, joining the company's Beckman Coulter, Leica Biosystems and Radiometer businesses.

Danaher's President and CEO, Thomas P. Joyce, Jr., said, "We expect Cepheid to be an excellent complement to our existing Diagnostics businesses and to expand our runway for growth across the platform. Cepheid's extensive installed base, test menu and innovative product offering contribute to its market leadership in molecular diagnostics and we expect it to strengthen our position in this high-growth segment."

Joyce continued, "By applying the Danaher Business System and combining Cepheid with our existing $5 billion revenue position in the diagnostics industry, we believe that Cepheid will be well-positioned to improve operational efficiencies, significantly expand margins and drive long-term growth. We look forward to welcoming the Cepheid team to Danaher."

Related Links:
Danaher
Cepheid

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.